| 國立成功大學 |
2023 |
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials
|
Wong, V.W.-S.;Tak, W.Y.;Goh, Goh G.B.B.;Cheng, P.-N.;Lawitz, E.J.;Younossi, Z.M.;Vuppalanchi, R.;Younes, Z.;Alkhouri, N.;Wang, L.;Liu, J.;Kersey, Kersey K.;Myers, R.P.;Harrison, S.A.;Goodman, Z.;Trauner, M.;Romero-Gomez, M.;Anstee, Q.M.;Nguyen, M.H.;Okanoue, T. |
| 臺大學術典藏 |
2022-08-19T00:20:47Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y. |
| 臺大學術典藏 |
2022-04-25T06:25:25Z |
Federated learning for predicting clinical outcomes in patients with COVID-19
|
Dayan I;Roth H.R;Zhong A;Harouni A;Gentili A;Abidin A.Z;Liu A;Costa A.B;Wood B.J;Tsai C.-S;Wang C.-H;Hsu C.-N;Lee C.K;Ruan P;Xu D;Wu D;Huang E;Kitamura F.C;Lacey G;de Ant?nio Corradi G.C;Nino G;Shin H.-H;Obinata H;Ren H;Crane J.C;Tetreault J;Guan J;Garrett J.W;Kaggie J.D;Park J.G;Dreyer K;Juluru K;Kersten K;Rockenbach M.A.B.C;Linguraru M.G;Haider M.A;AbdelMaseeh M;Rieke N;Damasceno P.F;e Silva P.M.C;Wang P;Xu S;Kawano S;Sriswasdi S;Park S.Y;Grist T.M;Buch V;Jantarabenjakul W;Wang W;Tak W.Y;Li X;Lin X;Kwon Y.J;Quraini A;Feng A;Priest A.N;Turkbey B;Glicksberg B;Bizzo B;Kim B.S;Tor-D?ez C;Lee C.-C;Hsu C.-J;Lin C;Lai C.-L;Hess C.P;Compas C;Bhatia D;Oermann E.K;Leibovitz E;Sasaki H;Mori H;Yang I;Sohn J.H;Murthy K.N.K;Fu L.-C;de Mendon?a M.R.F;Fralick M;Kang M.K;Adil M;Gangai N;Vateekul P;Elnajjar P;Hickman S;Majumdar S;McLeod S.L;Reed S;Gr?f S;Harmon S;Kodama T;Puthanakit T;Mazzulli T;de Lavor V.L;Rakvongthai Y;Lee Y.R;Wen Y;Gilbert F.J;Flores M.G;Li Q.; Dayan I; Roth H.R; Zhong A; Harouni A; Gentili A; Abidin A.Z; Liu A; Costa A.B; Wood B.J; Tsai C.-S; Wang C.-H; Hsu C.-N; Lee C.K; Ruan P; Xu D; Wu D; Huang E; Kitamura F.C; Lacey G; de Ant?nio Corradi G.C; Nino G; Shin H.-H; Obinata H; Ren H; Crane J.C; Tetreault J; Guan J; Garrett J.W; Kaggie J.D; Park J.G; Dreyer K; Juluru K; Kersten K; Rockenbach M.A.B.C; Linguraru M.G; Haider M.A; AbdelMaseeh M; Rieke N; Damasceno P.F; e Silva P.M.C; Wang P; Xu S; Kawano S; Sriswasdi S; Park S.Y; Grist T.M; Buch V; Jantarabenjakul W; Wang W; Tak W.Y; Li X; Lin X; Kwon Y.J; Quraini A; Feng A; Priest A.N; Turkbey B; Glicksberg B; Bizzo B; Kim B.S; Tor-D?ez C; Lee C.-C; Hsu C.-J; Lin C; Lai C.-L; Hess C.P; Compas C; Bhatia D; Oermann E.K; Leibovitz E; Sasaki H; Mori H; Yang I; Sohn J.H; Murthy K.N.K; Fu L.-C; de Mendon?a M.R.F; Fralick M; Kang M.K; Adil M; Gangai N; Vateekul P; Elnajjar P; Hickman S; Majumdar S; McLeod S.L; Reed S; Gr?f S; Harmon S; Kodama T; Puthanakit T; Mazzulli T; de Lavor V.L; Rakvongthai Y; Lee Y.R; Wen Y; Gilbert F.J; Flores M.G; Li Q.; WEICHUNG WANG |
| 臺大學術典藏 |
2021-09-01T01:54:24Z |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
|
ANN-LII CHENG; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. |
| 臺大學術典藏 |
2021-09-01T01:53:59Z |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
|
ANN-LII CHENG; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K. |
| 臺大學術典藏 |
2021-09-01T01:53:44Z |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study
|
Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
|
Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; Chiun Hsu; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. |
| 國立成功大學 |
2018 |
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
|
George, J.;Burnevich, E.;Sheen, I.-S.;Heo, J.;Kinh, N.V.;Tanwandee, Tanwandee T.;Cheng, P.-N.;Kim, D.Y.;Tak, W.Y.;Kizhlo, S.;Zhdanov, K.;Isakov, V.;Liang, Liang L.;Lindore, P.;Ginanni, J.;Nguyen, B.-Y.;Wahl, J.;Barr, E.;Robertson, M.;Ingravallo, P.;Talwani, R.;Investigators, on behalf of the C-CORAL Study |
